Patent ID: 6627662
Filing Date: 2003-09-30
Classification: A61K,A61P,C07C

Abstract:
A method for the treatment and/or prophylaxis of a subject afflicted with a condition where prolonged blockade of &bgr;1-adrenoreceptors is undesirable comprising intravenously administering to a subject afflicted with said condition, wherein said condition is selected from the group consisting of cardiac arrhythmia, acute myocardial infarction, and any other cardiac disorder where prolonged blockade of &bgr;1-adrenoreceptors is undesirable, an effective amount of a racemic or optically active &bgr;-blocker represented by formula (Ia) or a pharmaceutically acceptable acid addition salt thereof: whereinR is 3â€²,4â€²-dimethoxyphenyl, R1 is hydrogen, and R2 is selected from the group consisting of ethyl, propyl, isobutyl and isopropyl; or R is 4â€²-methoxyphenoxy, R1 is hydrogen, and R2 is selected from the group consisting of methyl, ethyl, propyl, isopropyl, isobutyl and cyclopropylmethyl; or a physiologically acceptable hydrolyzable derivative thereof wherein the hydroxy group in the 2-position of the 3-aminopropoxy side chain is esterified, whereupon said administering, said compound has an in vivo pharmacodynamic half-life of about 20 minutes or less.